NGNE
Price
$21.52
Change
+$0.23 (+1.08%)
Updated
Aug 7, 04:59 PM (EDT)
Capitalization
303.64M
OCUL
Price
$12.31
Change
-$0.19 (-1.52%)
Updated
Aug 7, 04:59 PM (EDT)
Capitalization
2.17B
95 days until earnings call
Interact to see
Advertisement

NGNE vs OCUL

Header iconNGNE vs OCUL Comparison
Open Charts NGNE vs OCULBanner chart's image
Neurogene
Price$21.52
Change+$0.23 (+1.08%)
Volume$400
Capitalization303.64M
Ocular Therapeutix
Price$12.31
Change-$0.19 (-1.52%)
Volume$15.65K
Capitalization2.17B
NGNE vs OCUL Comparison Chart in %
Loading...
NGNE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NGNE vs. OCUL commentary
Aug 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NGNE is a Buy and OCUL is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 08, 2025
Stock price -- (NGNE: $21.29 vs. OCUL: $12.50)
Brand notoriety: NGNE and OCUL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NGNE: 42% vs. OCUL: 117%
Market capitalization -- NGNE: $306.06M vs. OCUL: $2.17B
NGNE [@Biotechnology] is valued at $306.06M. OCUL’s [@Biotechnology] market capitalization is $2.17B. The market cap for tickers in the [@Biotechnology] industry ranges from $199.59B to $0. The average market capitalization across the [@Biotechnology] industry is $2.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NGNE’s FA Score shows that 0 FA rating(s) are green whileOCUL’s FA Score has 0 green FA rating(s).

  • NGNE’s FA Score: 0 green, 5 red.
  • OCUL’s FA Score: 0 green, 5 red.
According to our system of comparison, OCUL is a better buy in the long-term than NGNE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NGNE’s TA Score shows that 6 TA indicator(s) are bullish while OCUL’s TA Score has 3 bullish TA indicator(s).

  • NGNE’s TA Score: 6 bullish, 3 bearish.
  • OCUL’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, NGNE is a better buy in the short-term than OCUL.

Price Growth

NGNE (@Biotechnology) experienced а -2.65% price change this week, while OCUL (@Biotechnology) price change was +7.20% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.15%. For the same industry, the average monthly price growth was +8.44%, and the average quarterly price growth was +12.41%.

Reported Earning Dates

OCUL is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Biotechnology (+1.15% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
OCUL($2.18B) has a higher market cap than NGNE($304M). OCUL YTD gains are higher at: 46.370 vs. NGNE (-6.868). NGNE has higher annual earnings (EBITDA): -77.68M vs. OCUL (-176.35M). OCUL has more cash in the bank: 350M vs. NGNE (293M). NGNE has less debt than OCUL: NGNE (13.5M) vs OCUL (76.2M). OCUL has higher revenues than NGNE: OCUL (59.6M) vs NGNE (925K).
NGNEOCULNGNE / OCUL
Capitalization304M2.18B14%
EBITDA-77.68M-176.35M44%
Gain YTD-6.86846.370-15%
P/E RatioN/AN/A-
Revenue925K59.6M2%
Total Cash293M350M84%
Total Debt13.5M76.2M18%
FUNDAMENTALS RATINGS
NGNE vs OCUL: Fundamental Ratings
NGNE
OCUL
OUTLOOK RATING
1..100
7279
VALUATION
overvalued / fair valued / undervalued
1..100
67
Overvalued
57
Fair valued
PROFIT vs RISK RATING
1..100
10079
SMR RATING
1..100
9798
PRICE GROWTH RATING
1..100
4637
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a30

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

OCUL's Valuation (57) in the Pharmaceuticals Other industry is in the same range as NGNE (67) in the null industry. This means that OCUL’s stock grew similarly to NGNE’s over the last 12 months.

OCUL's Profit vs Risk Rating (79) in the Pharmaceuticals Other industry is in the same range as NGNE (100) in the null industry. This means that OCUL’s stock grew similarly to NGNE’s over the last 12 months.

NGNE's SMR Rating (97) in the null industry is in the same range as OCUL (98) in the Pharmaceuticals Other industry. This means that NGNE’s stock grew similarly to OCUL’s over the last 12 months.

OCUL's Price Growth Rating (37) in the Pharmaceuticals Other industry is in the same range as NGNE (46) in the null industry. This means that OCUL’s stock grew similarly to NGNE’s over the last 12 months.

OCUL's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as NGNE (100) in the null industry. This means that OCUL’s stock grew similarly to NGNE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NGNEOCUL
RSI
ODDS (%)
Bullish Trend 7 days ago
76%
Bearish Trend 2 days ago
82%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
85%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
MACD
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
85%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 16 days ago
85%
Bullish Trend 4 days ago
80%
Declines
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 8 days ago
85%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
NGNE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ISTAX25.67N/A
N/A
ICON Equity Investor
JAMCX35.68N/A
N/A
JPMorgan Mid Cap Value A
PQSAX25.15N/A
N/A
Virtus KAR Small-Cap Value A
TPLIX14.43N/A
N/A
Timothy Plan Large/Mid Cap Growth I
MMFFX14.27N/A
N/A
MM S&P 500® Index A